Eli Lilly and technology leader Nvidia have announced a collaboration to develop a new supercomputer that is set to become the most powerful system ever owned and operated by a pharmaceutical company.
According to Lilly’s October 28 announcement, the supercomputer will serve as the foundation for an “AI factory” — an advanced computing infrastructure designed to process massive datasets, train AI models on in-house experimental results, and generate new scientific insights. The system will be located within Lilly’s existing facilities and will operate entirely on renewable energy.
Lilly plans to harness this high-performance computing power for molecular discovery and to accelerate drug development timelines. Additionally, the company will make select AI models available through its TuneLab platform, which enables early-stage biotech companies to use Lilly’s tools in exchange for sharing training data to enhance future models.
“Lilly is shifting from using AI as a tool to embracing it as a scientific collaborator,” said Thomas Fuchs, Lilly’s senior vice president and chief AI officer. “This isn't just about speed, but rather interrogating biology at scale, deepening our understanding of disease and translating that knowledge into meaningful advances for people served by Lilly medicines as well as the broader life sciences ecosystem.”
The supercomputer will support applications such as reasoning-capable AI agents, advanced medical imaging, and digital twins that can integrate with Lilly’s robotic systems to accelerate manufacturing processes.
As the world’s first Nvidia DGX SuperPOD featuring DGX B300 systems, the supercomputer will run on a unified network powered by over 1,000 graphics processing units (GPUs).
Also Read